CD274, also known as programmed death ligand 1 (PD-L1), is a protein encoded by the CD274 gene in humans. This protein is a member of the B7 family of cell surface ligands that regulate T cell activation and immune responses. CD274 is primarily expressed on antigen-presenting cells such as dendritic cells and macrophages and can be upregulated in response to inflammatory signals. It can also be expressed by a variety of other cell types, including T cells, B cells, endothelial cells, and various tumor cells. CD274 binds to its receptor PD-1 on T cells, inhibiting T cell receptor signaling, reducing cytokine production and T cell proliferation. This phenomenon is a key immune evasion mechanism exploited by tumor cells. This has led to the development of PD-1/PD-L1 blockade therapy in cancer treatment, which aims to enhance anti-tumor immune responses by blocking the interaction between PD-1 and CD274.
Human CD274 Stable Cell Line - HEK293T is a highly advanced, efficient and stable cell line that can be used for a variety of biotechnology and scientific research purposes. HEK293T cells are derived from human embryonic kidney cells, are easy to grow and maintain, and are highly transfectable, making them easy to manipulate and introduce foreign genes. The CD274 protein is overexpressed in this cell line, allowing researchers to easily obtain large amounts of the protein for their studies.
CD274 (programmed death ligand 1, also known as B7H1) is expressed in both solid tumors and hematological malignancies, and it inhibits T cell function through its receptor programmed death 1 (PD-1), which is essential for tumor cells to escape immune surveillance. Here, researchers demonstrated that the levels of both phosphorylated JNK and Cyclin D2 were significantly downregulated in CD274-deficient leukemia-initiating cells (LICs). Overexpression of Cyclin D2 completely rescued the functional loss of CD274. In addition, CD274 directly associated with JNK and enhanced downstream signaling to increase Cyclin D2 levels, promoting leukemia development. Therefore, the surface immune molecule CD274 plays a key role in LIC proliferation. The CD274/JNK/Cyclin D2 pathway promotes LIC entry into the cell cycle, which may become a novel therapeutic target for the treatment of leukemia.
The researchers examined JNK signaling in WT and CD274-deficient LICs by Western blot analysis. The phosphorylation level of JNK was significantly reduced in CD274-deficient LICs (Figure 1a). Consistently, phosphorylated JNK expression was significantly increased when CD274 was overexpressed in 293T cells (Figure 1b). Interestingly, co-immunoprecipitation experiments showed that both JNK and phosphorylated JNK were pulled down by CD274 (Figure 1c). At the same time, CD274 was also detected upon JNK immunoprecipitation (Figure 1d).
Figure 1. CD274 interacts with JNK to increase Cyclin D2 levels. a Phospho-JNK and total JNK levels in WT and CD274-deficient LICs were determined by Western blot analysis. b Phospho-JNK and total JNK levels in CD274-overexpressing (OE) 293T cells were assessed by Western blot analysis. c Strep II tagged CD274 was overexpressed in 293T cells, followed by immunoprecipitation with Strep II beads and Western blotting analysis for the levels of CD274, phospho-JNK, and JNK. d Fc-tagged JNK was overexpressed in 293T cells, followed by immunoprecipitation with protein A/G beads, and the levels of CD274 and JNK were detected by Western blot analysis. (Fang X, et al., 2016)
The human CD274 stable cell line-HEK293T is mainly used in the field of scientific research. Specifically, the researchers used this stable cell line to study the protein programmed cell death ligand 1 (PD-L1), also known as CD274.
One of the main applications of the human CD274 stable cell line-HEK293T is the study of cancer immunotherapy. Another key application is drug discovery. Researchers can use these cells to develop and screen drugs that target PD-L1.
In addition, this cell line can be used in physiological and pathophysiological studies as well as in the study of disease mechanisms. For example, researchers can use these cells to gain insights into the regulation of immune evasion, antigen presentation, and T cell activation.
Finally, the human CD274 stable cell line - HEK293T is also critical for studying protein structure, function and interactions, all of which are critical for the discovery of new drugs.
Customer Reviews
Increased experimental throughput
Since switching to the Human CD274 Stable Cell Line-HEK293T, our screening assay throughput has increased significantly. The robustness of these cells has greatly reduced the variability we face in other cell lines, thereby increasing the efficiency of our drug discovery projects.
Great for immunotherapy research
This stable cell line has played an important role in our immunotherapy research. The reliable expression of CD274 provides us with a reliable model to explore potential therapeutic targets, making it a key component in our research toolkit.
Excellent cell viability
The viability and growth rate of the Human CD274 Stable Cell Line-HEK293T are excellent. Even after multiple passages, the cells maintain high viability and stable expression, which is critical for our long-term projects.
United Kingdom
09/09/2022
Write a Review